Vivo Capital
ANRO icon

Vivo Capital’s Alto Neuroscience ANRO Stock Holding History

Vivo Capital’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$34.7M Buy
1,359,915
+151,057
+12% +$4.54M 3.82% 8
2026
Q2 		$31.9M Buy
1,208,858
+173,307
+17% +$4.01M 2.91% 14
2026
Q1 		$23.3M Hold
1,035,551
– – 1.94% 18
2025
Q4 		$18.4M Buy
+1,035,551
New +$13M 1.19% 22

Other funds holding ANRO

Alpha Wave Global
Alpha Wave Global New York $4.27B AUM 12.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Spruce Street Capital
Spruce Street Capital New York $629M AUM 210.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Affinity Asset Advisors
Affinity Asset Advisors New York $2.46B AUM 196.28% 1-Year Est. Return
Eventide Asset Management
Eventide Asset Management Boston, Massachusetts $7.14B AUM 65.02% 1-Year Est. Return

Vivo Capital's ANRO Position: Q3 2026 in Review

Vivo Capital increased its Alto Neuroscience (ANRO) stake by 12% in Q3 2026, buying an estimated $4.54M and bringing the position to 1,359,915 shares worth $34.7M. The position accounts for 3.82% of the portfolio, ranked #8.

Vivo Capital first reported a position in ANRO in Q4 2025 and has held it in 4 quarters since. 87 funds tracked by Wall St. Rank hold ANRO as of Q3 2026.

  • Vivo Capital held 1,359,915 shares of Alto Neuroscience worth $34.7M as of Q3 2026.
  • Vivo Capital bought 151,057 Alto Neuroscience shares in Q3 2026, an estimated $4.54M.
  • Alto Neuroscience made up 3.82% of Vivo Capital's portfolio in Q3 2026, its #8 holding.
  • Vivo Capital first reported a position in Alto Neuroscience in Q4 2025 and has held it in 4 quarters since.
  • 87 funds tracked by Wall St. Rank held Alto Neuroscience as of Q3 2026.

Based on Vivo Capital's 13F filing for Q3 2026, filed 13 Nov 2026.